Sustained release of PTH(1–34) from PLGA microspheres suppresses osteoarthritis progression in rats
Source abstract
Abstract
We previously reported that PTH(1-34) inhibits the terminal differentiation of articular chondrocytes and, in turn, suppresses the progression of osteoarthritis (OA). However, this treatment requires an injection of PTH(1-34) once every 3 days over the treatment period. In this study, we studied the effect of sustained administration of PTH(1-34) in a papain-induced OA rat model. We developed an effective controlled-release system for prolonging the treatment duration of an intra-articular injection for OA treatment in rats. The effects of released PTH(1-34) from PLGA(65:35)-encapsulated PTH(1-34) microspheres (PTH/PLGA) on papain-induced OA in rat knees were studied. Microsphere morphology was observed in vitro by scanning electron microscopy, and microsphere size was determined with a particle size analyzer. The PTH(1-34) encapsulation efficiency and release profile, as well as the toxicity of PTH/PLGA, were examined. The bioactivity of released PTH(1-34) was tested by examining cAMP levels in MC3T3E1 cells. In vivo, we evaluated the changes of localized GAG, Col II, and Col X in the articular cartilage of rat knees. Our results demonstrated that the surface of the PLGA microspheres was smooth, and the size of the microspheres was in the range of 51-127 μm. PTH/PLGA microspheres sustainably released PTH(1-34) for 19 days with a concentration range of 0.01-100 nM that covered the expected concentration of 10nM at 37°C. The cAMP levels of MC3T3E1 cells were elevated in the response to released PTH(1-34) from PTH/PLGA microspheres, indicating that the released PTH(1-34) is bioactive. Most importantly, intra-articular treatment with either PTH(1-34) (0.1-100 nM) 3 days/injection or PTH/PLGA microspheres (15 days/injection) for 5 weeks revealed the similar effect on suppressing papain-induced OA changes (decreasing GAG and Col II and increasing Col X) in rat knee cartilage. The effect of PTH/PLGA microspheres on suppressing OA progression was similar to that of a once-every-three-day injection of PTH(1-34), indicating that both the sustained and intermittent action of PTH(1-34) effectively suppress OA progression. The developed PLGA microspheres with sustained release and long-term effect may be potent carriers for PTH(1-34) used to treat early OA.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Osteoarthritis Treatment and Mechanisms · Total Knee Arthroplasty Outcomes · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (15)
Show source-provided references
1. Complete aminoacid sequence of human parathyroid hormone10.1021/bi00619a019 ↗
2. Parathyroid hormone: synthesis, secretion, and action
3. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds10.1210/endo-112-3-1000 ↗
4. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone10.1002/jbmr.5650070110 ↗
5. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1–34) on rat bone
6. Parathyroid hormone 1–34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats10.1002/art.24843 ↗
7. Wu · 1995 · 1015
8. Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles10.1016/S0168-3659(00)00313-8 ↗
9. Biological activity of rhBMP-2 released from PLGA microspheres10.1115/1.429662 ↗
10. Controlled release of transforming growth factor beta1 from biodegradable polymer microparticles10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G ↗
11. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance10.1016/j.ejpb.2009.06.009 ↗
12. The effect of parathyroid hormone on the concentration of adenosine 3′,5′-monophosphate in skeletal tissue in vitro10.1016/S0021-9258(19)77126-9 ↗
13. Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment10.1359/jbmr.1999.14.9.1504 ↗
14. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis10.2165/00024677-200201030-00005 ↗
15. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1–34)10.1359/jbmr.2002.17.11.2038 ↗